Ipamorelin vs Sermorelin
How they differ on evidence quality, dosing schedule, half-life and cost.
| Ipamorelin | Sermorelin | |
|---|---|---|
| Evidence grade | CSmall or early human studies only | CSmall or early human studies only |
| Studied for | Selective growth-hormone peptide | Growth-hormone support peptide |
| Half-life | About 2 hours | About 11 to 12 minutes |
| Schedule | One to three times daily, subcutaneous | Once daily at night, subcutaneous |
| Amount in research | 200–300 mcg per dose | 100–300 mcg at bedtime |
| Vial sizes sold | 5 mg, 10 mg | 5 mg, 10 mg |
| Cost | $1.95 per dose | No verified price yet |
On evidence quality these two sit level, both graded C. Early studies confirm it raises growth hormone. No long-term outcome data. For Sermorelin: Human data is mainly historical pediatric use. Adult use is off-label with thin evidence. Nothing in the published record separates them, so a choice between them comes down to what is being studied and how it is dosed, and not to one having better support than the other.
An evidence grade describes how strong the research is, and it is not a safety rating or a recommendation. A higher grade on an approved drug does not make a research-use version of it approved.
Ipamorelin
It binds the ghrelin receptor on pituitary cells to trigger growth-hormone release. Its selectivity means it raises GH with little effect on cortisol, prolactin or appetite, unlike older secretagogues. The released GH then drives IGF-1 production that supports tissue repair and body composition. Human data is mostly short pharmacology work, and long-term outcome trials are lacking.
Sermorelin
Sermorelin is the first 29 amino acids of GHRH, the shortest piece that still triggers growth hormone release. It prompts the pituitary to put out its own growth hormone in normal pulses, which is why it was long used as a test of pituitary function and studied in growth hormone deficiency.
Ipamorelin
- Studied for raising natural growth-hormone and IGF-1 levels
- Researched for supporting recovery, lean mass and connective-tissue repair
- May improve sleep quality reported by some users of GH secretagogues
- Selective action means less effect on cortisol and prolactin than older peptides
Sermorelin
- Historically used to diagnose and treat childhood growth hormone deficiency.
- Stimulates the pituitary to release growth hormone by acting as a GHRH fragment.
- Studied for raised IGF-1 and possible body-composition effects in adults.
- May support sleep quality in some users through GH-axis effects.
Ipamorelin
- Water retention, tingling or numbness in the hands from higher GH levels
- Headache, flushing or lightheadedness after dosing
- Possible small rises in blood sugar over time
- Injection-site reactions
Sermorelin
- Injection-site pain, redness and swelling are common.
- Flushing, headache and dizziness reported.
- Fluid retention and joint discomfort from GH elevation.
- Adult long-term safety and benefit are not well established.
Which has better evidence, Ipamorelin or Sermorelin?
Neither. Both are graded C on our four-point scale, so the published record does not separate them.
How do the dosing schedules differ?
Ipamorelin: One to three times daily, subcutaneous. Sermorelin: Once daily at night, subcutaneous.
How do their half-lives compare?
Ipamorelin: About 2 hours. Sermorelin: About 11 to 12 minutes. Half-life is what the dosing frequency follows from.
Can Ipamorelin and Sermorelin be studied together?
Some research protocols pair compounds and some do not. There is no combined trial data for this pairing on file here, so treat any stacking claim you read elsewhere as untested.
Ipamorelin
Selective growth-hormone peptideA gentle peptide studied for prompting your own growth hormone with few side effects.
CSmall or early human studies onlySermorelin
Growth-hormone support peptideA gentle growth-hormone peptide that nudges the body to make more of its own.
CSmall or early human studies only